The use of antibiotic prophylaxis in neutropenic patients remains controversial. The main
arguments against prophylaxis are the lack of survival benefit and the risk of inducing …

Use of antibacterial prophylaxis in patients with chemothera... : Current Opinion in
Hematology Use of antibacterial prophylaxis in patients with chemotherapy-induced …

Patients with cancer and chemotherapy-induced neutropenia are at risk for severe bacterial
infections. This risk is not uniform among all cancer patients but is dependent primarily on …

Febrile neutropenia (FN) causes significant morbidity and mortality in patients receiving
cytotoxic chemotherapy and can lead to reduced chemotherapy dose intensity and …

Chemotherapy-induced neutropenia places patients with acute leukemia at high risk for
bacterial infections. A number of studies performed over the past 20 years have investigated …

New evidence shows that antibiotic prophylaxis in neutropenic patients reduces mortality,
febrile episodes, and bacterial infections. For patients with acute leukemia or those who …

Introduction: Neutropenia poses a serious threat to patients on chemotherapy. It exposes
them to the risk of infection–including potentially fatal infections–and also leads to delays in …

Current guidelines recommend that antibiotic prophylaxis is considered in all patients at
high and intermediate risk of febrile neutropenia. Clinical evidence now also supports …

A recent meta-analysis, which included non-placebo open-labeled trials, showed that
fluoroquinolone prophylaxis reduces mortality in neutropenic patients, whereas two recent …

Background Bacterial infections are a major cause of morbidity and mortality in patients who
are neutropenic following chemotherapy for malignancy. Trials have shown the efficacy of …